The generosity of an individual donor has enabled research that has the potential to transform treatment options for stage 3 lung cancer patients.

The study, which has now recruited its first patients, will identify the individual biomarkers found in patients with stage 3 lung cancer who are receiving combined chemotherapy and radiation therapy. Biomarkers are tiny particles found in the blood and tissue which indicate the presence of cancer.

The information will then be analysed to determine whether the presence or absence of certain biomarkers can be used to predict the outcome of these treatments. This research will help us better map the development of an individual patient’s cancer, and find more personalised ways to treat people living with lung cancer.

Dr Alex Davis, whose current position as Research Fellow is funded through this donation